GSK3739937 First-Time-In-Human (FTIH) Study in Healthy Volunteers
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- 48
Summary
- Conditions
- HIV Infections
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: RandomizedIntervention Model: Sequential AssignmentIntervention Model Description: Part 1 is a single ascending dose study, Part 2 is multiple ascending dose study while Part 3 is a 3-period crossover design.Masking: Double (Participant, Investigator)Masking Description: This will be a double-blind study with participants and the site-staff blinded and sponsor unblended. Part 3 of the study will be open-label.Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 55 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT04493684
- Collaborators
- Not Provided
- Investigators
- Study Director: GSK Clinical Trials ViiV Healthcare